Table 3.
Differences in clinicopathological characteristics of non-eligible omeprazole users and eligible omeprazole users
| Characteristics | Total |
EOG |
P value | |
| Non | Yes | |||
| Sex | ||||
| Male | 90 | 71 | 19 | 0.380 |
| Female | 35 | 25 | 10 | |
| Age(yr) | ||||
| < 60 | 73 | 58 | 15 | 0.410 |
| ≥ 60 | 52 | 38 | 14 | |
| BMI | ||||
| < 25 | 100 | 77 | 23 | 0.920 |
| ≥ 25 | 25 | 19 | 4 | |
| Tumor size (cm) | ||||
| ≤ 3 | 49 | 37 | 12 | 0.940 |
| 3-6 | 61 | 47 | 14 | |
| ≥ 6 | 15 | 12 | 3 | |
| Tumor grade | ||||
| 1 | 28 | 22 | 6 | 0.960 |
| 2 | 88 | 67 | 21 | |
| 3 | 9 | 7 | 2 | |
| cTNM | ||||
| II | 39 | 30 | 9 | 0.980 |
| III | 86 | 66 | 20 | |
| CEA (ng/mL) | ||||
| < 5 | 62 | 45 | 17 | 0.390 |
| ≥ 5 | 58 | 46 | 12 | |
| CA19-9 (U/mL) | ||||
| < 35 | 102 | 76 | 26 | 0.420 |
| ≥ 35 | 18 | 15 | 3 | |
| TGR | ||||
| 0 | 39 | 34 | 5 | 0.330 |
| 1 | 15 | 11 | 4 | |
| 2 | 20 | 16 | 4 | |
| 3 | 24 | 17 | 7 | |
| 4 | 27 | 18 | 9 | |
| CRT efficacy | ||||
| Poor | 74 | 61 | 13 | 0.072 |
| Good | 51 | 35 | 16 | |
| ypTNM | ||||
| ypcr | 25 | 16 | 9 | 0.380 |
| I | 26 | 21 | 5 | |
| II | 40 | 31 | 9 | |
| III | 34 | 28 | 6 | |
| Adjuvant CT | ||||
| No | 21 | 14 | 7 | 0.230 |
| Yes | 104 | 82 | 22 | |
| Recurrence | ||||
| No | 97 | 66 | 26 | 0.025 |
| Yes | 28 | 30 | 3 | |
EOG: Effective OME group; non-EOG: Non-effective OME group; BMI: Body mass index; TGR: Tumor regression grade; adjuvant CT: Adjuvant chemotherapy.